Treanda bendamustine: Phase II data

Data from an open-label, U.S. Phase II trial in 25 evaluable patients with relapsed or refractory indolent MCL showed that combination therapy with Treanda plus Velcade bortezomib and rituximab produced an overall response rate (ORR) of 84%, with 13 complete responses and 8 partial responses, plus 1 case of stable disease. Data will be presented at the American Society of Hematology meeting in New Orleans in December. ...